Intellia Therapeutics, Inc. (NTLA)
Automate Your Wheel Strategy on NTLA
With Tiblio's Option Bot, you can configure your own wheel strategy including NTLA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NTLA
- Rev/Share 0.5096
- Book/Share 6.8952
- PB 2.9644
- Debt/Equity 0.1434
- CurrentRatio 5.1932
- ROIC -0.6166
- MktCap 2194170350.0
- FreeCF/Share -4.0664
- PFCF -5.2017
- PE -4.4155
- Debt/Assets 0.1141
- DivYield 0
- ROE -0.5769
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NTLA | Wolfe Research | Peer Perform | Outperform | -- | $21 | April 21, 2025 |
| Initiation | NTLA | H.C. Wainwright | -- | Buy | -- | $30 | March 5, 2025 |
| Downgrade | NTLA | Goldman | Neutral | Sell | -- | $9 | Feb. 28, 2025 |
| Downgrade | NTLA | JP Morgan | Overweight | Neutral | $45 | $13 | Feb. 28, 2025 |
| Downgrade | NTLA | Morgan Stanley | Overweight | Equal Weight | $56 | $11 | Jan. 27, 2025 |
News
Levi & Korsinsky Reminds Intellia Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 – NTLA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129099&wire=1 or contact Joseph E. Levi, Esq.
Read More
Intellia Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129089&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Feb. 12, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA). The lawsuit alleges that Defendants made material misrepresentations concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease.
Read More
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 12, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129078&wire=1 or contact Joseph E. Levi, Esq.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Intellia Therapeutics, Inc. (NTLA)
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased the securities of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”).
Read More
Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129061&wire=1 or contact Joseph E. Levi, Esq.
Read More
NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Intellia securities between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period").
Read More
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Intellia Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of April 14, 2025
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA) between July 30, 2024 to January 8, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Marcos Gonzalez v.
Read More
About Intellia Therapeutics, Inc. (NTLA)
- IPO Date 2016-05-06
- Website https://www.intelliatx.com
- Industry Biotechnology
- CEO John M. Leonard
- Employees 403